[1] |
中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中国肝脏病杂志, 2019, 27(12):938-961.
|
[2] |
HOU J, WANG G, WANG F, et al. Guideline of prevention and treatment for chronic hepatitis B(2015 Update)[J]. J Clin Transl Hepatol, 2017, 5(4):297-318.
DOI
URL
|
[3] |
WONG D K H, SETO W K, CHEUNG K S, et al. Hepatitis B viruscore-related antigen as a surrogate marker for covalently closed circular DNA[J]. Liver Int, 2017, 37(7):995-1001.
DOI
URL
|
[4] |
NASSAL M. HBV cccDNA:viral persistence reservoir and key obstacle for a cure of chronic hepatitis B[J]. Gut, 2015, 64(12):1972-1984.
DOI
URL
|
[5] |
KÖCK J, THEILMANN L, GALLE P, et al. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus[J]. Hepatology, 1996, 23(3):405-413.
|
[6] |
CHOU S F, TSAI M L, HUANG J Y, et al. The dual role of an ESCRT-0 component HGS in HBV transcription and naked cappsid secretion[J]. PLoS Pathog, 2015, 11(10):e1005123.
DOI
URL
|
[7] |
PRAKASH K, RYDELL G E, LARSSON S B, et al. High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles[J]. Virol J, 2018, 15(1):86.
DOI
URL
|
[8] |
ROKUHARA A, MATSUMOTO A, TANAKA E, et al. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy[J]. J Gastroenterol, 2006, 41(8):785-790.
DOI
URL
|
[9] |
GUO J T, GUO H. Metabolism and function of hepatitis B vivus cccDNA:implications for the development of cccDNA-targeting antiviral therapeutics[J]. Antiviral Res, 2015, 122:91-100.
DOI
URL
|
[10] |
DING S, ROBEK M D. Cytidine deamination and cccDNA degradation:a new approach for curing HBV?[J]. Hepatology, 2014, 60(6):2118-2121.
DOI
URL
|
[11] |
CHEN J, WU M, LIU K, et al. New insights into hepatitis B virus biology and implications for novel antiviral straegies[J]. Nat Sci Rev, 2015, 2(3):296-313.
DOI
URL
|
[12] |
TSENG K C, CHENG P N, WU I C, et al. HBV DNA level as an important determinant of e antigen seroconver-sion of chronic hepatitis B during adefovir dipivoxil therapy[J]. Hepatogastroenterology, 2009, 56(91-92):813-818.
|
[13] |
VAN BÖMMEL F, BARTENS A, MYSICKOVA A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors[J]. Hepatology, 2015, 61(1):66-76.
DOI
URL
|
[14] |
WANG J, SHEN T, HUANG X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol, 2016, 65(4):700-710.
DOI
URL
|
[15] |
LAM A M, REN S, ESPIRITU C, et al. Hepatitis B virus capsid assembly modulators,but not nucleoside analogs,inhibit the production of extracellular pregenomic RNA and spliced RNA variants[J]. Antimicrob Agents Chemother, 2017, 61(8):e00680-17.
|
[16] |
VAN CAMPENHOUT M J H, VAN BÖMMEL F, PFEFFERKOM M, et al. Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment[J]. Hepatology, 2018, 68(3):839-847.
DOI
URL
|
[17] |
HONG X, KIM E S, GUO H. Epigenetic regulation of hepatitis B virus covalently closed circular DNA:implications for epigenetic therapy against chronic hepatitis B[J]. Hepatology, 2017, 66(6):2066-2077.
DOI
URL
|
[18] |
BELLONI L, ALLWEISS L, GUERRIERI F, et al. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome[J]. J Clin Invest, 2012, 122(2):529-537.
DOI
URL
|
[19] |
WOODDELL C I, YUEN M F, CHAN H L, et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg[J]. Sci Transl Med, 2017, 9(409):eaan0241.
|
[20] |
HUANG H, WANG J, LI W, et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals[J]. J Clin Virol, 2018, 99-100:71-78.
DOI
URL
|